Compare Ryanair Holdings plc (RYAAY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs Sanofi SA — how do they compare? Ryanair Holdings plc trades at $54.24 (market cap $27.11B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.5× Ryanair Holdings plc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Ryanair Holdings plc for 72 Days and Sanofi SA for 94 Days on average.
| RYAAY | SNY | |
|---|---|---|
Market Cap | $27.11B | $95.18B |
Volume | 2,427,380 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $73.82 | $52.34 |
52-Week Low | $51.95 | $39.51 |
Typical Hold Time | 72 Days | 94 Days |
Enterprise Value | $24.18B | $114.48B |
Dividend Yield | 1.66% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $54.24, down 3.14% on the day, with a bearish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 13.43 and net income margin of 12.13%, but recent earnings have missed expectations. Cash flow turned negative in 2025, and the company faces headwinds from high fuel costs and Boeing MAX 10 certification delays, as reported by Reuters on September 29, 2026.
The outlook is mixed: valuation appears attractive, and analyst consensus is moderately bullish with 64.71% buy ratings, but near-term risks from oil price volatility and operational challenges pressure the stock. Investors should weigh strong profitability and market position against earnings volatility and external uncertainties.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
